Labcorp Holdings is attracting fresh earnings optimism ahead of its June 2026 quarter, with analysts raising revenue and year-over-year earnings growth expectations. The stock has gained 11.9% over the past month and 17.9% year to date, closing recently at $296.77. A widely followed narrative pegs fair value at $310.12, implying the shares are 4.3% undervalued, while a discounted cash flow model suggests a much higher intrinsic value of $531.53. However, the current price-to-earnings ratio of 25.8 times sits slightly above the US healthcare industry average of 25.5 times and a modeled fair ratio of 25 times, raising questions about whether sentiment will align with cash flow estimates or if the multiple will contract. Key drivers include AI-powered operational efficiencies from platforms like eClaim Assist and Labcorp Diagnostic Assistant, as well as the Invitae integration, which is expected to be slightly accretive to full-year earnings.
Laboratory Corporation of America HoldingsAnalysts raise earnings expectations and DCF suggests 79% upside; stock seen 4.3% undervalued.